2018
The outcome of peripheral T-cell lymphoma patients failing first-line therapy: a report from the prospective, International T-Cell Project
Bellei M, Foss FM, Shustov AR, Horwitz SM, Marcheselli L, Kim WS, Cabrera ME, Dlouhy I, Nagler A, Advani RH, Pesce EA, Ko YH, Martinez V, Montoto S, Chiattone C, Moskowitz A, Spina M, Biasoli I, Manni M, Federico M. The outcome of peripheral T-cell lymphoma patients failing first-line therapy: a report from the prospective, International T-Cell Project. Haematologica 2018, 103: 1191-1197. PMID: 29599200, PMCID: PMC6029527, DOI: 10.3324/haematol.2017.186577.Peer-Reviewed Original ResearchConceptsBone marrow transplantationInternational T-cell ProjectPeripheral T-cell lymphoma patientsT-cell lymphoma patientsT-cell ProjectOverall survivalMarrow transplantationLymphoma patientsRelapsed Peripheral T-Cell LymphomaPeripheral T-cell lymphomaUnivariate Cox regression analysisChemotherapy-sensitive diseaseMedian overall survivalFirst-line therapyFirst-line treatmentOverall survival rateSurvival of patientsCox regression analysisEnd of treatmentStandard of careT-cell lymphomaMedian followPrimary refractoryBetter OSRefractory/
2007
Efficacy of Denileukin Diftitox in Subcutaneous Panniculitis-Like T-Cell Lymphoma
Hathaway T, Subtil A, Kuo P, Foss F. Efficacy of Denileukin Diftitox in Subcutaneous Panniculitis-Like T-Cell Lymphoma. Clinical Lymphoma Myeloma & Leukemia 2007, 7: 541-545. PMID: 18021473, DOI: 10.3816/clm.2007.n.040.Peer-Reviewed Original ResearchConceptsT-cell phenotypeDenileukin diftitoxSubcutaneous panniculitis-like T-cell lymphomaPanniculitis-like T-cell lymphomaSubcutaneous panniculitis-like lymphomaSystemic multi-agent chemotherapyAddition of bexaroteneMedian response durationMulti-agent chemotherapyComplete clinical regressionBone marrow transplantationT-cell lymphomaPleomorphic lymphocytesImmunosuppressive therapyRefractory patientsClinical regressionClinical responseMost patientsMarrow transplantationAggressive diseasePrognostic significanceDisease progressionRadiation therapyTraditional therapiesResponse duration
2006
The Role of Purine Analogues in Low-Intensity Regimens With Allogeneic Hematopoietic Stem Cell Transplantation
Foss FM. The Role of Purine Analogues in Low-Intensity Regimens With Allogeneic Hematopoietic Stem Cell Transplantation. Seminars In Hematology 2006, 43: s35-s43. PMID: 16549113, DOI: 10.1053/j.seminhematol.2005.12.007.Peer-Reviewed Original ResearchConceptsBone marrow transplantationAllogeneic stem cellsAcute GVHDConditioning regimensExtracorporeal photopheresisDendritic cellsAllogeneic hematopoietic stem cell transplantationLeukemia/lymphoma (GVL) effectT-cell-depleted graftsAllogeneic bone marrow transplantationHematopoietic stem cell transplantationDonor/recipient matchingAlternative stem cell sourceDonor dendritic cellsFull donor engraftmentHost dendritic cellsSevere acute GVHDTransplant-associated morbidityTransplant-associated toxicityMyeloablative conditioning regimensSeverity of GVHDT effector cellsT-cell depletionInduction of immunosuppressionStem cell transplantation
2004
Nucleoside analogs and antimetabolite therapies for myelodysplastic syndrome
Foss FM. Nucleoside analogs and antimetabolite therapies for myelodysplastic syndrome. Best Practice & Research Clinical Haematology 2004, 17: 573-584. PMID: 15494295, DOI: 10.1016/j.beha.2004.08.009.Peer-Reviewed Original ResearchConceptsMyelodysplastic syndromeAnti-vascular endothelial growth factorChemotherapeutic agentsAllogeneic bone marrow transplantationReceptor tyrosine kinase inhibitorsGrowth factorTransplant conditioning regimensBone marrow transplantationTyrosine kinase inhibitorsClonal hematopoietic disordersEndothelial growth factorNovel chemotherapeutic agentsMatrix metalloproteinase inhibitorsFarnesyl transferase inhibitorsIntensive chemotherapyConditioning regimensSupportive careFavorable cytogeneticsPrognostic factorsAntimetabolite therapyMarrow transplantationMDS patientsTreatment paradigmClinical trialsProtein kinase C inhibitor
2003
Peripheral T- cell lymphomas: diagnosis and management
Dearden CE, Foss FM. Peripheral T- cell lymphomas: diagnosis and management. Hematology/Oncology Clinics Of North America 2003, 17: 1351-1366. PMID: 14710889, DOI: 10.1016/s0889-8588(03)00119-9.Peer-Reviewed Original ResearchConceptsFirst-line therapyT-cell lymphomaCampath-1HResponse rateLine therapyPurine analoguesT-PLLAllogeneic bone marrow transplantationPeripheral T-cell lymphomaThird of patientsFavorable prognostic factorBone marrow transplantationMonoclonal antibody therapyStem cell transplantationNon-randomized studiesMature T-cell neoplasmsMinimal residual diseaseT-cell neoplasmsHigh response rateT-cell malignanciesLargest disease groupRisk of toxicityDurable remissionsRefractory patientsPreparative regimensReduced-intensity transplantation for patients with myelodysplastic syndrome achieves durable remission with less graft-versus-host disease
Chan GW, Foss FM, Klein AK, Sprague K, Miller KB. Reduced-intensity transplantation for patients with myelodysplastic syndrome achieves durable remission with less graft-versus-host disease. Transplantation And Cellular Therapy 2003, 9: 753-759. PMID: 14677114, DOI: 10.1016/j.bbmt.2003.08.002.Peer-Reviewed Original ResearchConceptsAcute GVHDHost diseasePreparative regimenExcess blastsAllogeneic transplantationDisease relapseGrade IIAllogeneic stem cell infusionReduced-intensity allogeneic transplantationReduced-intensity preparative regimenAllogeneic bone marrow transplantationHigh-risk MDS patientsExtensive chronic GVHDReduced-intensity transplantationTransplant-related mortalityFull donor chimerismTreatment-related mortalityStem cell infusionBone marrow transplantationMyelodysplastic syndrome patientsChronic myelomonocytic leukemiaSuccessful donor engraftmentChronic GVHDGVHD prophylaxisLess graftPersistence of host dendritic cells after transplantation is associated with graft-versus-host disease
Chan GW, Gorgun G, Miller KB, Foss FM. Persistence of host dendritic cells after transplantation is associated with graft-versus-host disease. Transplantation And Cellular Therapy 2003, 9: 170-176. DOI: 10.1016/s1083-8791(03)70006-8.Peer-Reviewed Original ResearchConceptsReduced-intensity preparative regimenHost dendritic cellsReduced-intensity regimenPreparative regimenTotal body irradiationDendritic cellsAcute GVHDChronic GVHDDC chimerismConventional regimenBody irradiationAllogeneic bone marrow transplantationAllogeneic bone marrow transplantAllogeneic stem cell transplantationExtensive chronic GVHDDevelopment of GVHDStem cell transplantationBone marrow transplantationBone marrow transplantExtracorporeal photophoresisHost diseaseMarrow transplantationSignificant morbidityMarrow transplantCell transplantation
2002
Immunologic mechanisms of extracorporeal photochemotherapy in chronic graft-versus-host disease
Gorgun G, Miller KB, Foss FM. Immunologic mechanisms of extracorporeal photochemotherapy in chronic graft-versus-host disease. Blood 2002, 100: 941-947. PMID: 12130506, DOI: 10.1182/blood-2002-01-0068.Peer-Reviewed Original ResearchConceptsMixed lymphocyte reactionAntigen-presenting dendritic cellsDendritic cellsT cellsChronic graftHost diseaseClinical responseDC populationsActivity of DCsAllogeneic bone marrow transplantationCD4/CD8 ratioMonocytic dendritic cellsAllogeneic T cellsEffector T cellsNatural killer cellsBone marrow transplantationTh2 cytokine profileChronic GVHDCD8 ratioCytokine profileECP therapyImmunologic mechanismsLymphocyte subpopulationsEffector lymphocytesKiller cells